Advertisement
Screener

Kyverna Therapeutics, Inc. (KYTX) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Kyverna Therapeutics, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Kyverna Therapeutics, Inc. pe ratio for the quarter ending 2026-06-30 was -3.6, a change of -2.76 year-over-year.
  • Kyverna Therapeutics, Inc. pe ratio for the quarter ending 2026-03-31 was -3.35, a change of -2.77 year-over-year.
  • Kyverna Therapeutics, Inc. pe ratio for the quarter ending 2025-12-31 was -3.51, a change of -2.24 year-over-year.
  • Kyverna Therapeutics, Inc. pe ratio for the quarter ending 2025-09-30 was -1.63, a change of 0.28 year-over-year.
  • Kyverna Therapeutics, Inc. pe ratio for fiscal 2026 was -3.6.
  • Kyverna Therapeutics, Inc. pe ratio for fiscal 2025 was -3.51, a change of -2.24 from fiscal 2024.
  • Kyverna Therapeutics, Inc. pe ratio for fiscal 2024 was -1.27.
Available history
2024-03-31 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-3.6$549.21M-$152.64M
2026-03-31-3.35$523.61M-$156.4M
2025-12-31-3.51$566.46M-$161.31M
2025-09-30-1.63$262.76M-$160.99M
2025-06-30-0.83$132.33M-$158.7M
2025-03-31-0.57$83.41M-$145.42M
2024-12-31-1.27$161.62M-$127.48M
2024-09-30-1.91$211.09M-$110.66M
2024-06-30-3.53$323.6M-$91.63M
2024-03-31-14.11$1.07B-$75.92M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-3.6$549.21M-$152.64M
2025-12-31-3.51$566.46M-$161.31M
2024-12-31-1.27$161.62M-$127.48M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Editas Medicine, Inc. (EDIT)United States$0.424B-4.29
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Zura Bio Ltd (ZURA)$0.398B-6.56
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Surrozen, Inc./DE (SRZN)United States$0.395B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
AGENUS INC (AGEN)United States$0.383B1.41
Entera Bio Ltd. (ENTX)$0.485B
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65